CN102526487A - Chinese medicament for treating immune thrombocytopenic purpura - Google Patents
Chinese medicament for treating immune thrombocytopenic purpura Download PDFInfo
- Publication number
- CN102526487A CN102526487A CN2012100724856A CN201210072485A CN102526487A CN 102526487 A CN102526487 A CN 102526487A CN 2012100724856 A CN2012100724856 A CN 2012100724856A CN 201210072485 A CN201210072485 A CN 201210072485A CN 102526487 A CN102526487 A CN 102526487A
- Authority
- CN
- China
- Prior art keywords
- radix
- itp
- blood
- chinese medicine
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicament for treating immune thrombocytopenic purpura (ITP). The medicament comprises 5 to 40 grams of rehmannia root, 1 to 30 grams of donkey-hide glue, 1 to 30 grams of Chinese angelica, 5 to 50 grams of pseudostellaria heterophylla, 2 to 50 grams of astragalus, 1 to 20 grams of rhubarb, 1 to 50 grams of agrimonia pilosa, 1 to 60 grams of fragrant solomonseal rhizome, and 1 to 50 grams of liquorice. The Chinese medicament has a definite effect of treating the ITP, is safe, and has few side effects and an extremely broad market prospect.
Description
Technical field
The invention belongs to tcm field, be specifically related to a kind of Chinese medicine of treating immunologic thrombocytopenic purpura.
Background technology
Immunologic thrombocytopenic purpura (Idiopathic Thrombocytopenic Purpura; ITP) be clinical common hemorrhage; With the peripheral blood thrombocytopenia, it is characteristic that bone marrow megakaryocyte increases companion's dysmaturity, is the hemorrhage syndrome of LADA.The maximum harm of primary disease is to cause coagulation disorders, and the lighter is mucocutaneous hemorrhage repeatedly, and obstinate causes anemia, serious appearance menorrhagia, even merge intracranial hemorrhage, in case threat to life takes place.
Along with raising China's new discovery in recent years patient of diagnosis is increase trend.According to statistics should the disease sickness rate, the America and Europe is 6～11,/10 ten thousand populations, and Japan is 16.7/10 ten thousand populations, and chronic ITP patient is mainly seen between the adult 20～50 years old, and gender's ratio is 1: 3.Modern medicine does not have the essence variation to the diagnoses and treatment of ITP over nearly one, 20 year; Treatment ITP mainly uses glucocorticoid and splenectomy; Though can make the part patient obtain clinical remission, relapse rate is higher, often can not maintain safety range because of platelet counts; Need further to adopt treatment measures such as immunosuppressant, androgen, bio-modification agent to keep platelet counts, to reduce mortality rate in normal range.But the life-time service said medicine can be brought and treat relevant a series of problems, and is not obvious like curative effect, relapse rate is high, organ injury, biochemical indicator unusual and medical fee raises up etc.
Therefore seek even more ideal medicine effective, that side reaction is few and become current research emphasis.Compare Chinese medicine with Western medicine and in this field of treatment, shown wide prospect.Chinese medicine has remarkable advantages aspect the treatment immunologic thrombocytopenic purpura, though it is comparatively slow with respect to hormone to promote the speed of platelet counts, late result is better, and can use repeatedly, no obvious adverse reaction.
Modern medicine is sent out speckle with the deficiency of YIN and is divided into two types of thrombocytopenic purpura (comprising constitutional and Secondary cases) and anaphylactoid purpura.From clinical characters, anaphylactoid purpura is more common in going out blood disorder, belonging to the YANG macule scope more of " bleeding due to blood-heat ", and it is main controlling with clearing away heat and cooling blood, promoting blood circulation and detoxication clinically.Thrombocytopenic purpura be mostly the hepatic and renal YIN deficiency, spleen lung qi weak due to, or insufficiency of kidney-YANG at a distance from sun in outside, or deficiency of the kidney yin, water loses heated, blood is robbed, or insufficiency of the spleenly can not take the photograph blood, or deficiency of the liver can not make so by store blood, in a word with weakened body resistance be main.The hepatic and renal YIN deficiency, spleen lung qi are weak, the deficiency of YIN is hot vehement, and blood loses quiet " eruption of YIN syndrome ", so with the moon of nourishing the liver and kidney, the gas of strengthening spleen and lung is helped the article of cooling blood for hemostasis slightly, and the cloudy multiple then empty positive intension of Liver and kidney, the spleen lung qi fills that then gas cloudy two is multiple, and the blood network is quiet, and all cards are pacified certainly.
The present invention is the basis with Chinese medicine to the syndrome of ITP comprehensive observing; Is point of penetration with modern medicine to the understanding of ITP, sets forth one's views from interior-heat caused by deficiency of YIN, thinks deficiency of the liver and kindey; Deficiency of YIN heat is vehement to be the main pathogenesis in ITP generation and the evolution; Propose nourishing YIN and clearing away heat, benefiting QI and nourishing blood is the basic principle of treatment ITP, has solid clinical theory and practice basis.
The Chinese medicine research worker of seminar of the present invention adopts the dialectical method that combines with differential diagnosis of diseases through clinical research in nearly 40 years, and the ITP that treats thousands of examples suffers from, and receives significant curative effect.Clinical manifestation in conjunction with ITP patient; Find that the ITP clinical disease is how relevant with interior-heat caused by deficiency of YIN; And to the unique opinion of ITP pathogenesis proposition; Find to have original curative effect on the nourishing YIN and clearing away heat ruling by law treatment ITP in the clinical research in early stage, obtained gratifying effect and favorable economic benefit and social benefit.
Through update search; Though some kind listings of direct or indirect treatment blood deficiency (anemia) are arranged; But the Chinese patent medicine that is specifically designed to ITP seldom; " XUEKANG KOUFUYE " (this product is a Chinese medicine extract) that the main wherein Pharmacopoeia of the People's Republic of China of the at present clinical ITP of being mainly used in treatment is 2000 editions one one, " weixuening electuary ", " the U.S. peace of blood capsule ".Though these kinds play a role in the control to primary disease, all there is not strong this unfavorable factor of specific aim.Comprehensive document in recent years, the ITP cause of disease can be summarized as diseases caused by exogenous pathogenic factor and internal injury; Pathogenesis can be summarized as: disturb (2) QI failing to control blood, (3) hyperactivity of fire caused by deficiency of YIN, (4) obstruction of collaterals by blood stasis in (1) evil poison.Above-mentioned each kind is this pathogenic characteristic of complete reaction not all.
Though the traditional Chinese medical science does not have this name of disease of idiopathic thrombocytopenic purpura, see with characteristicness such as various hemorrhage and ecchymosis petechias from the clinical of ITP, think that it belongs to " blood disorder " category of the traditional Chinese medical science.See that from chronic ITP clinical manifestation flickering, the touching deficiency of spleen-QI such as fatigue and weak, anorexia that more do not reach of common purpura show.For this reason, having proposed interior-heat caused by deficiency of YIN is the basic of ITP morbidity, recognizes the hepatic and renal YIN deficiency, the spleen lung qi is weak, the deficiency of YIN is hot vehement, and it is the main paathogenic factor of primary disease that blood loses quiet.So establish " nourishing YIN and clearing away heat " method of treatment.Use in prescription treatment ITP patient's in this clinical research in early stage, formulate efficacy assessment standard according to second national hematology's academic conference: produce effects, effective, progressive, invalid.100 routine ITP patients have been carried out observation of curative effect in more detail, and the result shows, obvious effective rate 65%, effective percentage 91.67%.Through long-term clinical observation, find this obviously relief of symptoms, and relapse rate is low, takes for a long time human body is not seen untoward reaction.
Through the clinical observation and the pharmacodynamic study of many decades, show that prescription treatment ITP patient receives comparatively satisfied curative effect in this.Till the present, do not see the Chinese patent medicine listing that special for treating should disease as yet, succeeding in developing of this medicine of the present invention will be filled up this blank; And treatment by Chinese herbs ITP determined curative effect, safety, few side effects, market prospect is extremely wide; In case put on market, will obtain good economic benefit and social benefit.Comprehensive statistics both domestic and external calculate by ten thousand/population, and will there be tens0000 patients in the whole nation, calculate need spend 1000 yuan of expensess for medicine a course of treatment, and year use amount is more than 100,000,000 yuan, and market potential is huge.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine of treating immunologic thrombocytopenic purpura, this treatment by Chinese herbs ITP determined curative effect, safety, few side effects, market prospect is extremely wide.
The invention provides a kind of Chinese medicine of treating immunologic thrombocytopenic purpura, this medicine is formed as follows: Radix Rehmanniae 5-40g, Colla Corii Asini 1-30g, Radix Angelicae Sinensis 1-30g; Radix Pseudostellariae 5-50g, Radix Astragali 2-50g, Radix Et Rhizoma Rhei 1-20g; Herba Agrimoniae 1-50g, Rhizoma Polygonati Odorati 1-60g, Radix Glycyrrhizae 1-50g.
The Chinese medicine of treatment immunologic thrombocytopenic purpura provided by the invention, this medicine is formed preferably as follows: Radix Rehmanniae 10-30g, Colla Corii Asini 5-20g, Radix Angelicae Sinensis 5-15g; Radix Pseudostellariae 10-30g, Radix Astragali 15-25g, Radix Et Rhizoma Rhei 4-10g; Herba Agrimoniae 15-30g, Rhizoma Polygonati Odorati 15-25g, Radix Glycyrrhizae 10-20g.
The Chinese medicine of treatment immunologic thrombocytopenic purpura provided by the invention, this medicine is formed most preferably following: Radix Rehmanniae 20g, Colla Corii Asini 12g, Radix Angelicae Sinensis 10g, Radix Pseudostellariae 24g, Radix Astragali 20g, Radix Et Rhizoma Rhei 6g, Herba Agrimoniae 20g, Rhizoma Polygonati Odorati 20g, Radix Glycyrrhizae 15g.
The Chinese medicine of treatment immunologic thrombocytopenic purpura provided by the invention, said Radix Et Rhizoma Rhei are the processed with wine processed product.
The effect of the Chinese medicine of treatment immunologic thrombocytopenic purpura provided by the invention: benefiting qi and nourishing yin, nourishing blood and hemoslasis.
Curing mainly of the Chinese medicine of treatment immunologic thrombocytopenic purpura provided by the invention: deficiency of both QI and YIN, purpura due to the knot in the QI failing to control blood, blood stasis.Obstinate disease, the hematohidrosis that shows effect repeatedly, the petechia ecchymosis, the extremity asthenia, shortness of breath and fatigue is had a dizzy spell, inappetence, the loose stool, or epistaxis, have blood in stool, hematuria etc., body of the tongue is dim or petechia, thready and weak pulse arranged.
The side of the Chinese medicine of treatment immunologic thrombocytopenic purpura provided by the invention separates: Radix Astragali replenishing QI to invigorate the spleen, and the Rhizoma Polygonati Odorati Yin-nourishing and body fluid promoting, two medicines share, and benefiting qi and nourishing yin is monarch drug.Radix Angelicae Sinensis, Colla Corii Asini, the Radix Rehmanniae, Herba Agrimoniae nourish blood, YIN nourishing, hemostasis, and Radix Angelicae Sinensis is joined the Radix Astragali with benefiting QI and nourishing blood, and invigorating blood circulation, it is just wonderful not hinder; The Radix Et Rhizoma Rhei blood stasis dispelling that purges heat, Radix Angelicae Sinensis helps Radix Et Rhizoma Rhei to lead to blood network, removing blood stasis blood, makes hemostasis not stay the stasis of blood, and the not removing blood stasis of invigorating blood circulation is ministerial drug altogether.The Radix Pseudostellariae strongly invigorating primordial QI is joined the Radix Astragali and both can have been made to have under one's command and have the right, and can make the prosperous blood of gas capable again.Be adjuvant drug altogether.Make with Radix Glycyrrhizae and middle tonify deficiency, coordinating the actions of various ingredients in a prescription.We's strengthening vital QI to eliminate pathogenic factors is taken into account, and is intended to delay attack blood stasis, makes the stasis of blood go new life, and is then sick from recovery from illness.Full side's compatibility is done in the proper way, makes the strong then QI can control blood of temper, and blood stasis goes then blood can return through, fresh blood and gives birth to then hemorrhage from ending.
Immunologic thrombocytopenic purpura (ITP) is common clinically hemorrhagic, autoimmune disease, and with the periphery thrombocytopenia, megakaryocytic hyperplasia of bone marrow companion dysmaturity is a characteristic.Rising year by year along with the ITP sickness rate; The change of generation and bone marrow megakaryocyte that can confirm ITP about the clinical and basic research of ITP to a certain extent is closely related, and the propagation of bone marrow megakaryocyte, differentiation, ripe up to the cytokine network regulation and control of hematoblastic production process by complicacy.Regulate cytokine IL-3, IL-6, IL-11, TGF-β 1, the effect of TPO in the ITP morbidity that megalokaryocyte generates, using for clinical rational provides experimental basis.
IL-3 is important hemopoietic regulatory factor, is the main component of immune system hemopoietic system, and hematopoietic cell especially megalokaryocyte is had important regulation.The mechanism of IL-3 increased platelets counts is through acting on early stage hemopoietic progenitor cell; Promote its propagation; And promote the differentiation of hemopoietic progenitor cell, thereby finally promote hematoblastic generation with kit-ligand and differentiation factor in late period (like erythropoietin, granulocyte colony-stimulating factor, M-CSF etc.).
IL-6 promotes that macronucleus is hemopoietic and the hematoblastic key factor of generation, the effect that promotes that macronucleus precursor colony forms is arranged, but stimulating megakaryocyte DNA is proteic synthetic, and the effect that promotes that megakaryocyte proliferation maturation and platelet discharge is arranged.IL-6 raises; Activating immune system, the differentiation of stimulation B cell increases the generation of platelet-associated antibody; Cause hematoblastic destruction to be increased; And the antiplatelet antibody in the serum is destroying the hematoblastic while, and this antibody can stimulate the bone marrow megakaryocyte compensatory hypertrophy, to increase the platelet counts in the circulation.Clinical ITP patients serum IL-6 level is detected, find normally obviously to raise, treatment is alleviated the back and is descended, and raises once again during recurrence, and then the state of an illness of ITP is heavy to show the IL-6 height.This result confirms that also blood serum IL-6 has practical relation with ITP really, so the detection blood serum IL-6 can be research ITP cause and onset of disease mechanism theoretical foundation is provided, and simultaneously, helps the clinical observation state of an illness, judges curative effect, estimates prognosis.
IL-11 is a kind of by the excretory cytokine with multiple function of hematopoieticmicroenviron-ment marrow stromal cell; It also is important hemopoietic regulatory factor; In recent years as promoting the thrombopoietic factor extremely to pay attention to; It can be combined on the memebrane protein of extracellular matrix and stromal cell, thereby brings into play hemopoietic regulating and controlling effect efficiently.External report thinks that IL-11 level and platelet are the negative feedback regulatory mechanism, and IL-11 is also regulated by different inflammatory mediators except that the adjusting based on the periphery platelet count.
Select for use and the closely-related technical specification of ITP pathogenesis through experiment, part has disclosed the ITP mechanism.The result shows that Hemopoietic factor IL-3, IL-6, IL-11, TGF-β 1, TPO and ITP morbidity are closely related.This discovers, purpura can be the imbalance state through adjustment Hemopoietic factor IL-3, IL-6, IL-11, TGF-β 1, TPO, promotes platelet counts and improves platelet function, promotes link such as bone marrow megakaryocyte maturation and get effect.This important discovery has science and practical value to development ITP Chinese medicine new theory and direct clinical, and is significant to the modern difficult treatment theory of performance Chinese medicine.
TGF-β 1 suppresses thrombopoietic Hemopoietic factor.
TPO regulates megakaryocyte proliferation, differentiation, maturation and then forms hematoblastic main positive sex factor, also is that an early stage hemopoietic promotes the factor, can promote Megakaryocytic maturation and hematoblastic generation.The specific stimulation megakaryoblast proliferation and differentiation of ability promotes megakaryocytic maturation also to produce platelet.This result of study shows that model group medullary cell TPO level obviously increases, and presents decline in various degree through behind the drug treatment.Positivity acting factor as megakaryocyte growth; Supposition possibly be that the especially original macronucleus of bone marrow megakaryocyte, inmature macronucleus increase the negative regulation effect of having brought into play during owing to ITP; When the periphery platelet destruction increases and when causing platelet counts to descend; Bone marrow megakaryocyte quantity compensatory increases, and TPO is discharged in the blood, causes the concentration of medullary cell TPO obviously to increase.This and domestic and foreign literature are reported consistent.
The multiformity relation of multifarious group effect of Chinese medicine ingredients and cytokine secretion; See from immune pharmacology angle; Possibly to be them regulate sex material base according to functional status in the body different being to the included multiple composition of Chinese medicine itself, and rely this always trend in returning within the physiological equilibrium from pathological state; And can improve body's immunological function on the whole through each ingredient in the cytokine network.The whole concept system that this and the traditional Chinese medical science are traditional is perfectly in harmony, and the research of therefore being devoted to Chinese medicine pair cell factor regulating action seems very necessary.
The specific embodiment
The following example is in order to further specify the present invention, rather than will limit its scope.
Embodiment 1
Respectively with Radix Rehmanniae 20g, Colla Corii Asini 12g, Radix Angelicae Sinensis 10g, Radix Pseudostellariae 24g, Radix Astragali 20g, Radix Et Rhizoma Rhei 6g, Herba Agrimoniae 20g, Rhizoma Polygonati Odorati 20g, Radix Glycyrrhizae 15g are mixed and made into and control ITP Chinese medicine.Embodiment 2
Respectively with Radix Rehmanniae 10g, Colla Corii Asini 5g, Radix Angelicae Sinensis 5g, Radix Pseudostellariae 10g, Radix Astragali 15g, Radix Et Rhizoma Rhei 4g, Herba Agrimoniae 15g, Rhizoma Polygonati Odorati 15g, Radix Glycyrrhizae 10g are mixed and made into and control ITP Chinese medicine.
Embodiment 3
Respectively with Radix Rehmanniae 30g, Colla Corii Asini 20g, Radix Angelicae Sinensis 15g, Radix Pseudostellariae 30g, Radix Astragali 25g, Radix Et Rhizoma Rhei 10g, Herba Agrimoniae 30g, Rhizoma Polygonati Odorati 25g, Radix Glycyrrhizae 20g are mixed and made into and control ITP Chinese medicine.
Embodiment 4
84 SPF level BLAB/c mices are divided into 7 groups by the peripheral blood platelet number, promptly normal group, model group, Chinese medicine matched group 1 (weixuening), Chinese medicine matched group 2 (the U.S. peace of blood), control ITP Chinese medicine (prescription of embodiment 1) high dose group, control dose groups in the ITP Chinese medicine (prescription of embodiment 1), control ITP Chinese medicine (prescription of embodiment 1) low dose group.Every group 12.Through the variation of ITP model mice peripheral blood platelet number, investigate the effect intensity of treatment herbs intervention ITP, through Hemopoietic factor IL-3, IL-6, IL-11, TGF-β 1, TPO changes of contents, investigate the drug effect mechanism of treatment herbs intervention ITP.
This research experiment result shows, with normal group comparatively speaking, model group mice peripheral blood platelet number obviously descends, except that the weixuening group, each administration group all has the effect that promotes platelet count in various degree.Controlling the middle dose groups lifting of ITP Chinese medicine (purpura granule) peripheral blood platelet number aspect obviously is superior to weixuening group, the U.S. peace group of blood, controls ITP Chinese medicine high and low dose group.
Early-stage Study shows that prednisolone acetate fast lifting peripheral blood platelet number aspect is superior to the purpura granule; But along with the prolongation of administration time, platelet count then has downward trend, explains that its ascending platelet effect has the tendency that weakens; The short term effect that also reflects hormone is better, and late result is relatively poor.But in the purpura granule three groups, the speed that promotes platelet count is not as prednisone, but along with the prolongation of time, promotes hematoblastic curative effect and obviously strengthen and longer duration the advantage of no significant side effects.Because chronic ITP has outbreak tendency repeatedly, the prolonged application hormone has significant side effects, and late result is undesirable; And the Chinese medicine stable curative effect, no significant side effects not only can improve number of platelets; Also can improve platelet function, obviously improve hemorrhage situation.
Table 1 ITP mice peripheral blood platelet number (
K/ μ l)
Annotate: compare with normal group,
★P＜0.05; Compare with model group,
▲P＜0.05; Contrast 1 weixuening group relatively with Chinese medicine,
■P＜0.05; Contrast the U.S. peace group of 2 blood relatively with Chinese medicine,
●P＜0.05; Compare between each treatment group,
1) 2) 3)P＜0.05.
Table 2 respectively organize mouse bone marrow cells IL-3, IL-6, IL-11 concentration comparison (
ng/L, n=8)
Annotate: compare with normal group,
★P＜0.05; Compare with model group,
▲P＜0.05; Compare with the Chinese medicine matched group,
■P＜0.05.
Table 3 is respectively organized mouse bone marrow cells TGF-β
1, TPO concentration comparison (
Ng/L, n=8)
Annotate: compare with normal group,
★P＜0.05; Compare with model group,
▲P＜0.05; Compare with the Chinese medicine matched group,
■P＜0.05.
Can be known that by table 1 model group and normal group compare, ITP mice peripheral blood platelet number obviously descends, and except that the weixuening group, each administration group all has the effect that promotes platelet count in various degree.The middle dose groups of controlling ITP Chinese medicine promotes peripheral blood platelet number aspect and obviously is superior to weixuening group, the U.S. peace group of blood, controls ITP Chinese medicine high and low dose group.
Can know by table 2,3; Model group medullary cell IL-3, IL-11 concentration obviously raise than normal group; Raise to ITP treatment back medullary cell IL-3, IL-11, TPO concentration; Supposition possibly be because the peripheral blood platelet number descends, and has stimulated the medullary cell increment, thereby makes the medullary cell secretion discharge IL-3, IL-11, the increase of TPO concentration.ITP model blood serum IL-6 concentration is normal obviously to raise, give control ITP Chinese medicine after blood serum IL-6 concentration obviously descend, clinical research raises when finding the ITP recurrence once again, then the state of an illness of ITP is heavy to show the IL-6 height.ITP model group medullary cell TGF-β
1Level obviously increases, and presents decline in various degree through behind the drug treatment.
Research shows, it is closely related that IL-3, IL-6, IL-11, TGF-β 1, TPO and ITP fall ill, participated in should disease immunoreation.Show that simultaneously purpura side has the effect of obvious lifting ITP model mice peripheral blood platelet number, infer that it possibly be to generate different Hemopoietic factors through regulation and control megalokaryocyte and platelet to reach " enrich blood, hemostasis, blood stasis dispelling " and act on.
Claims (4)
1. Chinese medicine of treating immunologic thrombocytopenic purpura is characterized in that: this medicine is formed as follows: Radix Rehmanniae 5-40g, Colla Corii Asini 1-30g, Radix Angelicae Sinensis 1-30g; Radix Pseudostellariae 5-50g, Radix Astragali 2-50g, Radix Et Rhizoma Rhei 1-20g; Herba Agrimoniae 1-50g, Rhizoma Polygonati Odorati 1-60g, Radix Glycyrrhizae 1-50g.
2. according to the Chinese medicine of the said treatment immunologic thrombocytopenic purpura of claim 1, it is characterized in that: this medicine is formed as follows: Radix Rehmanniae 10-30g, Colla Corii Asini 5-20g; Radix Angelicae Sinensis 5-15g, Radix Pseudostellariae 10-30g, Radix Astragali 15-25g; Radix Et Rhizoma Rhei 4-10g; Herba Agrimoniae 15-30g, Rhizoma Polygonati Odorati 15-25g, Radix Glycyrrhizae 10-20g.
3. according to the Chinese medicine of the said treatment immunologic thrombocytopenic purpura of claim 2, it is characterized in that: this medicine is formed as follows: Radix Rehmanniae 20g, Colla Corii Asini 12g, Radix Angelicae Sinensis 10g, Radix Pseudostellariae 24g, Radix Astragali 20g, Radix Et Rhizoma Rhei 6g, Herba Agrimoniae 20g, Rhizoma Polygonati Odorati 20g, Radix Glycyrrhizae 15g.
4. according to the Chinese medicine of the said treatment immunologic thrombocytopenic purpura of claim 1-3, it is characterized in that: said Radix Et Rhizoma Rhei is the processed with wine processed product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210072485 CN102526487B (en) | 2012-03-19 | 2012-03-19 | Chinese medicament for treating immune thrombocytopenic purpura |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210072485 CN102526487B (en) | 2012-03-19 | 2012-03-19 | Chinese medicament for treating immune thrombocytopenic purpura |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526487A true CN102526487A (en) | 2012-07-04 |
| CN102526487B CN102526487B (en) | 2013-11-06 |
Family
ID=46335307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210072485 Active CN102526487B (en) | 2012-03-19 | 2012-03-19 | Chinese medicament for treating immune thrombocytopenic purpura |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526487B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105833014A (en) * | 2016-05-23 | 2016-08-10 | 上海市青浦区中医医院 | Traditional Chinese medicine composition for treating thrombocytopenic purpura and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015607A (en) * | 2006-12-27 | 2007-08-15 | 辽宁中医药大学 | Traditional Chinese medicine for treating immune thrombocytopenic purpura and preparing method thereof |
| CN101254275A (en) * | 2008-03-10 | 2008-09-03 | 屈凤星 | Chinese medicine for curing aplastic anemia |
| CN102106995A (en) * | 2009-12-23 | 2011-06-29 | 孙明丽 | Chinese medicine preparation for treating recurrent respiratory tract infection of pediatric patient with chronic idiopathic thrombocytopenic purpura |
-
2012
- 2012-03-19 CN CN 201210072485 patent/CN102526487B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015607A (en) * | 2006-12-27 | 2007-08-15 | 辽宁中医药大学 | Traditional Chinese medicine for treating immune thrombocytopenic purpura and preparing method thereof |
| CN101254275A (en) * | 2008-03-10 | 2008-09-03 | 屈凤星 | Chinese medicine for curing aplastic anemia |
| CN102106995A (en) * | 2009-12-23 | 2011-06-29 | 孙明丽 | Chinese medicine preparation for treating recurrent respiratory tract infection of pediatric patient with chronic idiopathic thrombocytopenic purpura |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105833014A (en) * | 2016-05-23 | 2016-08-10 | 上海市青浦区中医医院 | Traditional Chinese medicine composition for treating thrombocytopenic purpura and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526487B (en) | 2013-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101015607A (en) | Traditional Chinese medicine for treating immune thrombocytopenic purpura and preparing method thereof | |
| CN105311219A (en) | Health Jieyu Ningshen mixture | |
| CN102526487B (en) | Chinese medicament for treating immune thrombocytopenic purpura | |
| CN103800888B (en) | A kind of Chinese medicine composition treating neurasthenia | |
| CN101214289B (en) | Chinese medicinal composition for treating thrombocytopenic purpura and preparation thereof | |
| CN100544755C (en) | Medicament for treatment of leukemia | |
| CN102423335B (en) | Medicine combination for treating impotence and premature ejaculation and preparation method thereof | |
| CN103446272A (en) | Composition for improving sleep, and preparation method and use thereof | |
| CN103948888A (en) | Traditional Chinese medicinal preparation for treating neurasthenia | |
| CN102526539B (en) | Traditional Chinese medicinal compound for treating idiopatic thrombocytopenic purpura (ITP) | |
| CN103055164B (en) | Traditional Chinese medicine composition for treating isolated diastolic hypertension | |
| CN102920836A (en) | Traditional Chinese medicine composite for treating immune thrombocytopenic purpura | |
| CN103495108B (en) | Medicine for treating chronic hypotension and preparation method for medicine | |
| CN102048939A (en) | Medicament for treating sinus bradycardia | |
| CN105343518A (en) | Traditional Chinese medicine formula for treating chronic aplastic anemia and preparation method thereof | |
| CN105056049A (en) | Pharmaceutical composite for treating pulmonary tuberculosis | |
| CN105560757A (en) | Medicine for treating nail ringworm | |
| CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
| CN104043085A (en) | Traditional Chinese medicine for treating vomitus gravidarum | |
| CN107441219B (en) | Pharmaceutical composition for improving immune function of acquired immune deficiency syndrome and application thereof | |
| CN103272122A (en) | Traditional Chinese medicinal composition for treating Chronic aplastic anemia | |
| CN105796989A (en) | Traditional Chinese medicine composition for treating leukemia | |
| CN106074837A (en) | A kind of suppression and removing platelet antibody, the Chinese medicine composition for the treatment of idiopathic thrombocytopenic purpura | |
| CN104173563A (en) | Traditional Chinese medicine composition for treating idiopathic thrombocytopenic purpura | |
| CN103494904B (en) | One treats neurasthenic Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |